Login to Your Account

Glionova gets $6M in series A for new approach in cancer

By Cormac Sheridan
Staff Writer

Thursday, November 13, 2014
DUBLIN – Glionova AB, a Swedish start-up exploiting a novel mechanism of action in cancer, raised SEK42 million (US$5.7 million) in a series A round to take forward its lead drug, GLN-1001, which is in development for glioblastoma.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription